Comparative Risk of Metabolic Adverse Outcomes in Patients With Schizophrenia Treated With Aripiprazole Versus Olanzapine: A Retrospective Cohort Study Using the TriNetX Network

Author Information

• Cameron C. Asay, Drexel University College of MedicineFollow
• Kypros Dereschuk, Drexel University College of MedicineFollow
• Eduardo Espiridion, Drexel University College of MedicineFollow

Keywords:

Aripiprazole, Olanzapine, Schizophrenia Spectrum Disorder, Metabolic Complications, TriNetX.

Recommended Citation

Asay, Cameron C.; Dereschuk, Kypros; and Espiridion, Eduardo, "Comparative Risk of Metabolic Adverse Outcomes in Patients With Schizophrenia Treated With Aripiprazole Versus Olanzapine: A Retrospective Cohort Study Using the TriNetX Network" (2026). Tower Health Research Day. 29.
https://scholarcommons.towerhealth.org/th_researchday/2025-2026/in_person_posters/29

Institutional Review Board/Institutional Animal Care and Use Committee Approved or Exempt

Not Applicable